ACHILLES THERAPEUTICS PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.752 USD | -2.89% |
|
-3.95% | -15.41% |
Presenter SpeechLee Stern (Executives)Thank you for joining us today. I am Lee Stern, Vice Pre...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.
Calendar
2024-04-28
- Chardan Cell Therapy Manufacturing Summit
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
0.7744
USD
Average target price
4.125
USD
Spread / Average Target
+432.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -15.41% | 31.81M | |
| +1.80% | 42.59B | |
| +7.95% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +9.25% | 24.81B | |
| -24.34% | 18.17B | |
| +28.24% | 12.05B | |
| -3.34% | 11.7B | |
| +6.99% | 11.1B |
- Stock Market
- Equities
- ACHL Stock
- News Achilles Therapeutics plc
- Transcript : Achilles Therapeutics plc - Special Call
